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Abstract
This is a retrospective study about the prevalence of ESBL-producing Escherichia coli (EEC) in urinary
specimens from patients from the Comunitat Valenciana from January 2007 to December 2008. Data were retrieved
from RedMIVA, and Bayesian generalized linear mixed models were considered to study the prevalence of EEC with
regard to demographical and microbiological factors.
The total number of infections considered was 164,502, the amount of urinary isolates was 70,827 belonging to
49,304 different patients, and 5,161 (7.3%) of the urinary isolates were EEC. Three out of four E. coli were isolated
in women (76.8%), men showed higher rates of EEC (9.7% in men vs. 6.5% in women). EEC patients were, in
average, 10.8 years older, and hospitalization was more frequent (9.9% vs. 6.9%).
Resistance to non-β-lactams antimicrobials was higher in EEC. The rates of ciprofloxacin and co-trimoxazol
resistance in EEC were 75.5% and 52.0%, respectively, whereas it ranged between 1.4-12.4% for the rest of
antimicrobials.
Prior EEC infection and hospitalization were the most relevant risk factors and increased the expected EEC
probability approximately 400% and 50% respectively. Other infections played an important and positive role too,
Enterobacteriaceae, P. aeruginosa and other bacteria being the most relevant elements. Female gender was a
protective factor and reduced the risk by approximately 25% while age was an additive risk factor.
Finally, an open-access web-based software was constructed to compute the probability that an E. coli in a
urinary infection be an EEC from a specific combination of risk factors. This pharmacovigilance tool should prove
useful to monitor and control antimicrobial resistance spread.
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Introduction
ESBL-producing Escherichia coli (EEC) has arisen and
disseminated worldwide as an important cause of both nosocomial
and community infections [1-4] and nowadays represents a major
threat [5]. This has called for a re-evaluation of susceptibility
interpretation and current antimicrobial therapies [6,7]. Early
identification of potential EEC carriers is the first step to withhold the
dispersal of these microorganisms and to avoid possible complications
[2,8,9]. Therefore, surveillance for EEC at every level –i.e., national,
regional, local or within the hospital- is critical in order to adequately
design recommendations, for epidemiological and spread control
purposes, as well as for an empirical treatment of infections caused by
this microorganism, especially due to the complications derived from
an inadequate antibiotherapy [2,7,10].
The objective of this paper is to discuss the probability of carrying
an EEC for a specific individual with a urinary tract infection (UTI),




This is a retrospective study about the prevalence of EEC in urinary
specimens from patients from the Comunitat Valenciana, an
autonomous region in the East of Spain with a population of 5,029,601
and a surface equal to 23,255 km2, which was divided geographically
into 22 health departments at the time of the study.
Urinary isolates were obtained from January 2007 to December
2008. Microbial identification and antimicrobial susceptibility testing
were performed according to each laboratory standard procedures and
conforming to CLSI antimicrobial susceptibility criteria, either by
regular biochemical reactions and agar diffusion susceptibility tests or
by automated methods.
Data collection
Data were retrieved from the Comunitat Valenciana
Microbiological Surveillance Network (RedMIVA), which daily
compiles and analyzes information from 25 microbiology laboratories
that manage more than 90% of the total population. Relevant
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demographic and microbiological data from all patients in the study
were recorded. Such data included age, gender, health department,
hospitalization by any cause and any other prior bacterial infection
taking place during the study period. Likewise, information about
susceptibility for the following antimicrobial agents was retrieved:
amikacin, tobramycin, ciprofloxacin, fosfomycin, nitrofurantoin, and
trimethoprim-sulfamethoxazole.
EEC was defined as an E. coli resistant to third generation
cephalosporins but susceptible to amoxicillin-clavulanate. Thus most
of the ESBLs encountered clinically -TEM, SHV and CTX-M-type
enzymes (functional group 2be from the Bush-Jacoby-Medeiros
classification) - were taken into account [11].
Statistical methodology
Bayesian generalized linear mixed models [12] were considered to
study the prevalence of EEC with regard to the demographical and
microbiological factors considered. Markov Chain Monte Carlo
methods were applied for approximating the posterior distribution for
the relevant parameters and hyperparameters of the model through
the free software WinBUGS 1.4.3 [13].
We considered a general scenario with non-informative prior
knowledge but, in order to avoid any chance of obtaining improper
prior distributions, we have always worked with proper densities:
Normal distributions with large variance (10^6) are elicited as the
prior distribution for the coefficients of the model and, a hierarchical
normal prior distribution for the geographical random effect. A vague
uniform hyperprior distribution, Uniform (0,2), for the standard
deviation of that geographical effect is considered. In addition, we did
a sensitivity analysis based on different Normal prior distributions for
the regression coefficients with a wide range of possible values for the
variance together with Uniform distributions for the standard
deviation with values for the maximum larger than 2. With all these
elicitations we always obtained the same posterior distribution, and
not only with the WinBUGS software but also through the R INLA
package [14].
In order to construct the statistical model, the random variable Yij
takes the value 1 when specimen i from a patient located in health
department j (sij) is ECC, and 0 otherwise. This variable was defined in
terms of a Bernouilli distribution with probability pij, which is
connected to the values of the different factors (gender,
hospitalization, health department, presence or not of previous
infections by E. coli, by EEC, by Enterobacter spp., by
Enterobacteriaceae, by Pseudomonas aeruginosa, by Enterococcus
faecalis, by Staphylococcus aureus and by Other bacteria) and
covariate (age) in the study through the logit transformation:
Yi j∼Bernou lli p i j ,
log it(pij = α0 +α1l Women Si j +α2l Hospita l Si j +
                   +α3kl E. coli Si j +α3kl EEC Si j +α5l Enterobac ter Si j +
                   +α6l Enterobac ter iaceae Si j +α7l P. aer ug inosa Si j
                   +α8l Other  Bac ter ia Si j +α9l E. f aeca lis Si j +
                   +α10l S. a ureus Si j +α11Age Si j +uj
where I{A}(sij) stands for the indicator function defined as 1 if
specimen sij –i.e. the patient who has provided it- has had the
characteristic A, and zero otherwise (for example, I{Woman} (sij) would
be equal to 1 if the person providing specimen sij were a woman), Age
(sij) is the age in years of the patient who supplies specimen sij and ui
represents the random effect corresponding to health department j.
This model is re-parameterized considering as the baseline the
group defined by men, non-hospitalized, with no previous infections
by E. coli, by EEC, by Enterobacter spp., by Enterobacteriaceae, by P.
aeruginosa, by E. faecalis, by S. aureus and by other bacteria. Note that
the intercept α0 in the model is the element that reflects the effect of
this baseline group in the logit probability for ECC rather than directly
on this probability.
Results
The total number of infections considered was 164,502, while the
amount of urinary isolates analyzed was 70,827 belonging to 49,304
different patients. Of the urinary isolates, 5,161 (7.3%) were
categorized as EEC. Three out of four E. coli were isolated in women
(76.8%), however men showed higher rates of EEC (9.7% in men vs.
6.5% in women). EEC patients were, in average, 10.8 years older, and
hospitalization was more frequent too (9.9% vs. 6.9%). Demographic
data are summarized in Table 1.
E.coli ESBL-E.coli Total
Number of isolates 65,666 5,161 70,827
Mean Age (yrs) 52.5 63.3 53.3
Gender  
Women 50,831 (93.5) 3,558 (6.5) 54,389
Men 14,835 (90.2) 1,603 (9.6) 16,438
Hospitalization  
Yes 8,874 (90.1) 978 (9.9) 9,852
No 56,792 (93.1) 4,183 (6.9) 60,975
Table 1: Demographic data (n(%)).
E. coli and EEC antimicrobial resistance data to different
antimicrobial agents is displayed in table 2. It is worth mentioning that
the number of isolates fluctuates depending on the antimicrobial
considered from 60,267 in the case of amikacin to 64,404 for
ciprofloxacin. Resistance to non-β-lactams antimicrobials was
considerably higher in EEC patients. In particular, the rates of
ciprofloxacin and co-trimoxazol resistance were 75.5% and 52.0%
respectively, whereas that rate ranges between 1.4 % and 12.4 % for the
rest of antimicrobials.
Approximate posterior summaries of the statistical analysis are
presented in table 3: posterior mean and 95% credible interval for each
of the unknown elements in the model and posterior mean and 95%
probability interval for the odds ratio of each factor, except for the
geographical one. The results are rather concluding since 0 is not
included in the 95% credible interval of any risk factor. The sign of
each posterior mean reveals if the corresponding risk factor acts
increasing (+) or decreasing (-) the EEC probability.
A previous EEC infection appears as the most eminent risk factor
and increases slightly more than four times the expected EEC
probability. Hospitalization is the second most relevant factor and
increases the expected EEC probability approximately 50%.
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 E.coli ESBL-E.coli Total
Amikacin  
n 60,267 5,022 65,289
Resistance 173 (0.3) 68 (1.4) 241 (0.4)
Tobramycin  
n 62,775 5,058 67,833
Resistance 3370 (5.4) 627 (12.4) 3997 (5.9)
Nitrofurantoin  
n 63,095 5,050 68,145
Resistance 1018 (1.6) 197 (3.9) 1215 (1.8)
Ciprofloxacin  
n 64,404 5,127 69,531
Resistance 17,889 (27.8) 3,870 (75.5) 21,759 (31.3)
Co-trimoxazol  
n 62,146 4,999 67,145
Resistance 20,364 (32.8) 2,598 (52.0) 22,962 (34.2)
Fosfomycin  
n 62,789 4,999 67,788
Resistance 1,337 (2.1) 219 (4.4) 1,556 (2.3)





Odds ratio (Mean (95%
CI))
Intercept -3.658 (-3.940, -3.453)
woman -0.293 (-0.357, -0.227) 0.746 (0.700, 0.797)
age 0.015 (0.014, 0.016) 1.015 (1.014, 1.016)
hospitalized 0.360 (0.278, 0.436) 1.433 (1.321, 1.546)
E. coli infection 0.248 (0.178, 0.313) 1.281 (1.195, 1.368)
Enterobacter spp. 0.174 (0.089, 0.258) 1.190 (1.093, 1.295)
Other Enterobacteria 0.294 (0.116, 0.446) 1.342 (1.124, 1.562)
Other bacteria 0.282 (0.218, 0.344) 1.326 (1.244, 1.411)
P. aeuroginosa 0.290 (0.145, 0.436) 1.337 (1.156, 1.547)
E. coli ESBL 1.448 (1.351, 1.542) 4.255 (3.861, 4.675)
E. faecalis 0.234 (0.123, 0.343) 1.264 (1.131, 1.409)
S. aureus 0.110 (-0.076, 0.286) 1.116 (0.927, 1.331)
Geographical effect 0.482 (0.337, 0.694)  
Table 3: Parameters and odds ratios: mean and 95% credible interval
(CI).
Other infections play an important and positive role in the EEC
prevalence, Enterobacteriaceae, P. aeruginosa and other bacteria being
the most relevant factors.
Age might seem rather insignificant, but since it is additive, it
becomes relevant past middle age.
Female gender always acts as a protective factor; actually, being a
woman reduces the risk by approximately 25% with regard to men.
Discussion
The major findings of this study are: i) the correlation between EEC
and higher resistance levels to non-β-lactams antimicrobials, especially
ciprofloxacin; ii) a higher proportion of EEC in men, older individuals,
hospitalized patients and its association with previous infections,
especially previous ECC; and iii) that the probability that an E. coli in a
urinary infection be an EEC can be predicted for an individual with a
specific combination of risk factors.
First of all, we would like emphasize that the aim of this paper was
to approach EEC from a pragmatic point of view, since our goal was to
build a statistical model to explain how different risk factors interact
and modulate ECC acquisition in order to predict its emergence.
In agreement with other papers [15,16], we have found a direct
correlation between EEC and higher resistance levels to non-β-lactams
antimicrobials commonly used for community or nosocomial UTI. It
is well known that ESBL-carrying plasmids can also confer resistance
to other antimicrobials [16-18], but the alarming level of resistance to
ciprofloxacin in EEC among our population, which is higher than that
of other studies conducted in Spain [1,19,20], indicates a very close
relationship in the transmission of ESBL and quinolone resistance
which should be borne in mind by practitioners. Yet, amikacin,
fosfomycin and nitrofurantoin remained as good therapeutic options
due to the low resistance levels found, as described in prior studies
[21]. All of this should be taken into account when issuing local
guidelines for empirical antimicrobial treatment of UTI.
Risk factors inherent to the host like age or gender play an essential
role in EEC occurrence. Older age is commonly accepted as a risk
factor [4,22]; our study demonstrates how age is a constantly growing
risk factor that becomes relevant from maturity on. This fact probably
reflects a cumulative exposure to risk factors through time. Gender is a
more controversial issue: our study agrees with Condoner et al. that
found male gender as a risk factor, while female gender always acts as a
protective factor, contrary to statements found in other papers [22-24].
Hospitalization is a commonly accepted risk factor [1]. In our
study, it increased by 50% the probability of carrying an EEC. Possible
explanations for this are higher antibiotic pressure, higher
concentration of EEC and therefore, close contact and interaction with
EEC carriers within the hospital setting. But, whatever the reason is,
the item hospitalization acts as a surrogate of different risks factors [4],
which leads us to the next point: previous infections.
Numerous studies have tried to identify which antimicrobials were
more likely to increase EEC prevalence, but they often obtain different
results. While many of them find third generation cephalosporins and
quinolones as relevant key factors, others fail to obtain the same
results; instead, they talk about second generation cephalosporins,
penicillins or just “antibiotics” [1,4,15,19,24-26]. Furthermore, an
antimicrobial that is found to be a risk factor in a bivariate analysis is
not in a multivariate analysis in the same paper [23]. These
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discrepancies are most likely based on different antimicrobial policies,
due to the prevalent ESBL enzymes or ESBL-carrying plasmids from
each region [17], or even to the analysis methodology [27-29]. We
tried to amend such potential confounders by identifying the
infections and microorganisms involved that were relevant to our
statistical modelling and use them as indicators of antimicrobial
treatments. Eventually, we found out several microorganisms that
were relevant. The first and more obvious factor was previous
infections by EEC, indicating that the individual has been previously
exposed to that microorganism and has apparently incorporated it
into the bacterial flora. Next, infections by Enterobacteriaceae and P.
aeruginosa; both of them are associated with the use of cephalosporins
and quinolones, which are important for ECC emergence. P.
aeruginosa is also related to patients with underlying conditions [30],
and so are more likely associated to invasive procedures or
antimicrobial prophylaxis. Other infections that were important in our
model, all as independent risks factors, argue chiefly for the use of a
wide range of antimicrobials. Interestingly, infections by Gram-
positive bacteria such as E. faecalis, intrinsically resistant to
cephalosporins, seem also important and highlight the relevance of
other antimicrobials in the selection and emergence of EEC.
Finally, all the data was used to construct a statistical model with
the aims of explaining how different risk factors interact and
describing EEC in our region. The most interesting feature of this
model is its capacity for making predictions for EEC. For such reason,
an open-access web-based implementation has been constructed in
order to compute and display the posterior predictive distribution for
an EEC regarding the values of the relevant risk factors and covariate
from the last two years that could be accessible to every medical
practitioner and, given the time, could be automated. This tool should
be very useful for clinicians, microbiologists and epidemiologists when
the time comes to prescribe empirical treatments for UTI or to prevent
EEC from spreading. Moreover, our methodology can easily be used in
other populations regardless of their antimicrobial policies or
microorganism features.
One of the limitations of our study is that we retrieved the data
from different hospitals and that these data were basically phenotypic.
Studying the original bacteria in order to get genetic information
would have been beyond price due to the large number of infections
analyzed. Nevertheless, one of the major strengths of our study is
precisely the great amount of data analyzed, using the same criteria for
all the isolates.
In conclusion, we have been able to describe EEC in our population
through Bayesian inference, providing our health system with a tool
that could be essential for EEC control and surveillance. The use of a
large database such as RedMIVA has been the cornerstone of this
paper.
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